Signals, Powered By EquityPandit
Strides Shasun’s wholly owned subsidiary, Strides Pharma Global Pte has received approval from Unites States Food and Drug Administration (USFDA), for Efavirenz Tablets USP, 600 mg.
The tablet which received approval, is the generic version of Sustiva Tablets of Bristol-Myers Squibb Company. The product will be manufactured at the company’s Oral dosage facility at Banglore and will be marketed by Strides Pharma Inc. in the US market.
Further, the product will launched immediately and the company has 74 cumulative ANDA filings with USFDA, out of which 44 ANDAs have been approved and 30 are pending for approval.
